Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T-Cell Lymphoma: early-phase trial registry
12 of 17 indexed T-Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 12 currently recruiting · #1,004 of 28,707 conditions by registered trial count
T-Cell Lymphoma: 17 US clinical trials tracked, 12 recruiting.
T-Cell Lymphoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 2 of these trials.
Enrollment posture brief
Registry condition t-cell-lymphoma
OPEN 12 | RECR 71% | LATE 0 | EARLY 16 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Ewing Sarcoma (70% recruiting · 27 trials)
T-Cell Lymphoma lists 12 open slots (71% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for T-Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
T-Cell Lymphoma is recruiting above its size-band peers.
12 of 17 indexed trials (70.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of T-Cell Lymphoma trials is spread across many organizations.
Yale University accounts for 2 of 17 trials (11.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most T-Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 16 trials that report a genuine target (sentinel values excluded). 11 of those (68.8%) plan for fewer than 100 participants.
-
T-Cell Lymphoma research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Registry for People With T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05978141
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
NCT06492304
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT04752826
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT06390319
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development
NCT04234048
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT07356245
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
NCT05313243
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
NCT05983965
A Study of Enasidenib in People With T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06756308
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
NCT05996185
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Cancer Institute (NCI)
NCT07388563
CD4CAR for CD4+ Leukemia and Lymphoma
Huda Salman
NCT03829540
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
Corvus Pharmaceuticals
NCT03952078
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Washington University School of Medicine
NCT04331119
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Rigel Pharmaceuticals
NCT00798096
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Weill Medical College of Cornell University
NCT00161590
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on T-Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on T-Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this T-Cell Lymphoma page
17 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 T-Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Yale University sponsors the most T-Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Yale University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This T-Cell Lymphoma condition card totals 17 registered trials; most-linked intervention Total lymphoid irradiation (TLI); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.